The biggest recent DSIP news came from a July 24, 2026 FDA advisory committee meeting. At that session, FDA reviewers evaluated delta sleep-inducing peptide under the common name emideltide. Agency staff proposed keeping both emideltide free base and emideltide acetate off the 503A Bulks List.
That committee process is advisory rather than a final rule or an approval decision. There is no FDA-approved medicine containing either form, and DSIP is not FDA-approved. Even so, a licensed provider may still prescribe — that decision is between you and your doctor.
Here is what changed between July and October 2026, along with the standing research on DSIP.
Changelog
September 21, 2026 — WADA publishes the 2027 Prohibited List. The World Anti-Doping Agency's 2027 Prohibited List, effective January 1, 2027, names neither DSIP nor emideltide.
However, WADA's Section S0 bans any unaddressed pharmacological substance lacking current government regulatory approval for human therapeutic use. Because an unlisted name does not clear a peptide for sport, tested athletes should check with their anti-doping organization.
August 2026 — Quiet month. The searches used for this update found no DSIP-specific dated development in August 2026.
July 24, 2026 — FDA staff review emideltide. At the July 23–24, 2026 PCAC meeting, FDA reviewers evaluated emideltide free base and emideltide acetate. In FDA's July 24 presentation slides, staff reviewed human reports on chronic insomnia, narcolepsy, and opioid withdrawal.
FDA staff proposed that neither emideltide form be added to the 503A Bulks List. Committee recommendations are nonbinding, and FDA sets the final list only through notice-and-comment rulemaking.
October 2026 DSIP news: where FDA rulemaking stands
As of October 17, 2026, the day this article was written, FDA's July meeting page links no minutes, transcript, or vote tally. Checked Federal Register searches from July 24 through October 17, 2026 also found no DSIP-specific or emideltide-specific proposed or final rule.
On FDA's Section 503A bulk substances page, the agency notes that nominated ingredients are evaluated through notice-and-comment rulemaking. Meanwhile, FDA's 503A interim categories document still carries its May 14, 2026 update date. Neither DSIP nor emideltide appears in Category 1, Category 2, or Category 3 of that list.
A separate federal filing arrived in October outside the third-quarter changelog window. On October 14, 2026, the Office of Information and Regulatory Affairs logged an FDA notice under review number RIN 0910-ZD94. The filing is titled "Interim Access Policy for Compounding Using Certain Peptides"; OIRA concluded its review on October 27, 2026.
On October 28, 2026, HHS filed the resulting draft peptide policy for Federal Register publication on October 30. Appendix A names BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500; DSIP is not among them. For how the committee process works across peptides, read our overview of the FDA peptide decision.
Inside FDA's emideltide review: half-life, routes, and safety
Readers checking DSIP update 2026 records often ask why FDA documents use the name emideltide. FDA's July slides explain that emideltide is a common name for DSIP rather than an official naming designation. Reviewers evaluated emideltide free base and emideltide acetate separately because nominations covered both raw forms of the peptide.
A drug's plasma half-life is the time it takes the level in the blood to fall by half. In FDA's emideltide briefing document, reviewers reported an 8-minute plasma half-life after intravenous administration. That fast blood clearance does not establish how long any effect lasts or when to dose before sleep.
FDA also found no human pharmacokinetic (absorption and clearance) data for the proposed subcutaneous (under-the-skin) route. Across the studies FDA reviewed, 209 people received intravenous emideltide at 25 to 150 nmol/kg for 1 to 15 days. Three subjects in an older withdrawal study experienced serious adverse effects.
Two of those subjects developed low blood pressure (hypotension) at the first injection. One of the two had progressive hypotension after a second dose. The third subject had repeated 15-minute episodes of general discomfort with sweating and nausea.
Because those events occurred during opioid withdrawal, other medical factors were present. As a result, those old papers cannot set a side-effect rate for current products.
Still, FDA concluded that intravenous safety is insufficiently characterized and noted that subcutaneous use lacks clinical safety data. Reviewers also flagged possible immune reactions if subcutaneous peptides clump together or carry impurities, as covered in DSIP side effects.
| Review area | What FDA's July 2026 emideltide review reported |
|---|---|
| Ingredient forms | Emideltide (free base) and emideltide acetate |
| Approval status | DSIP is not FDA-approved; neither form is in an approved drug |
| Uses reviewed | Chronic insomnia, narcolepsy, and opioid withdrawal |
| Plasma half-life | 8 minutes (IV); no subcutaneous pharmacokinetic data |
| Human IV exposure | 209 subjects over 1 to 15 days (25 to 150 nmol/kg) |
| Serious adverse effects | 3 subjects: hypotension (2) and recurrent discomfort with sweating and nausea (1) |
| Staff proposal | Do not add either form to the 503A Bulks List |
Standing facts and latest DSIP research
As of October 17, 2026, the day this article was written, PubMed searches found no new DSIP papers since July 1, 2026. Those searches cover indexed medical journals rather than unindexed studies or ongoing work. The standing evidence below comes from older studies.
First, Schoenenberger and Monnier described DSIP in a 1977 Proceedings of the National Academy of Sciences paper. They identified a nine-amino-acid sequence in a study of 58 rabbits, including controls, rather than in humans.
Second, Kovalzon and Strekalova examined that rabbit cerebral venous blood finding in a 2006 Journal of Neurochemistry review. Their 2006 review noted that researchers had not isolated a DSIP gene, protein, or receptor, as explained in what DSIP is.
Third, human studies were small and mostly intravenous. In a 1992 double-blind study in Neuropsychobiology of 16 chronic insomnia patients, intravenous DSIP showed weak objective changes and no subjective sleep improvement.
Our guide to DSIP benefits and clinical studies covers those trials in detail. Fourth, there is no FDA-approved drug containing emideltide, and DSIP is not FDA-approved.
What a provider considers before prescribing DSIP
DSIP prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. Because DSIP has no standardized product label, no universal dose or schedule applies to every patient.
When someone asks about poor sleep, a clinician evaluates why sleep is disrupted rather than assuming a peptide deficiency. As the National Heart, Lung, and Blood Institute's insomnia diagnosis guide explains, a provider first reviews sleep patterns and daytime fatigue. The clinician also checks current medicines and any caffeine, nicotine, alcohol, or substance use.
Loud snoring or waking up gasping for air may prompt a clinician to consider a sleep study to check for sleep apnea. FDA's briefing book notes that medical guidelines recommend cognitive behavioral therapy first for chronic insomnia. Opioid withdrawal is usually managed under medical supervision rather than with an unsupervised peptide plan.
A reviewing clinician also checks blood-pressure history and sedating medications before making a decision. At Promise, a licensed provider reviews every request and not everyone qualifies.
